IE59293B1 - Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions - Google Patents
Pharmaceutical 9,10-dihydro ergot alkaloid containing compositionsInfo
- Publication number
- IE59293B1 IE59293B1 IE29186A IE29186A IE59293B1 IE 59293 B1 IE59293 B1 IE 59293B1 IE 29186 A IE29186 A IE 29186A IE 29186 A IE29186 A IE 29186A IE 59293 B1 IE59293 B1 IE 59293B1
- Authority
- IE
- Ireland
- Prior art keywords
- formulation according
- fatty material
- dergocrine
- dihydroergotamine
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 229960003133 ergot alkaloid Drugs 0.000 title claims abstract description 25
- 238000009472 formulation Methods 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 21
- 229960004704 dihydroergotamine Drugs 0.000 claims abstract description 20
- 230000008961 swelling Effects 0.000 claims abstract description 19
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims abstract description 17
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940074979 cetyl palmitate Drugs 0.000 claims abstract description 11
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000013270 controlled release Methods 0.000 claims abstract description 9
- SBFXHXZNBNFPHV-PXXBSISHSA-N epicriptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)[C@H](C)CC)C(C)C)=C3C2=CNC3=C1 SBFXHXZNBNFPHV-PXXBSISHSA-N 0.000 claims abstract description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 6
- 239000000194 fatty acid Substances 0.000 claims abstract description 6
- 229930195729 fatty acid Natural products 0.000 claims abstract description 6
- -1 fatty acid ester Chemical class 0.000 claims abstract description 6
- 206010027599 migraine Diseases 0.000 claims abstract description 6
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 4
- 229920002678 cellulose Polymers 0.000 claims abstract description 4
- 239000001913 cellulose Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002746 orthostatic effect Effects 0.000 claims description 3
- 229930015720 peptide alkaloid Natural products 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 230000036543 hypotension Effects 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960004943 ergotamine Drugs 0.000 claims 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 abstract description 4
- 229920000609 methyl cellulose Polymers 0.000 abstract description 4
- 239000001923 methylcellulose Substances 0.000 abstract description 4
- 239000000416 hydrocolloid Substances 0.000 abstract description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000000470 constituent Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- 229950001817 alpha-ergocryptine Drugs 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical class CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000001407 Vascular Headaches Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 3
- 229960004290 dihydroergocornine Drugs 0.000 description 3
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 3
- 229960004318 dihydroergocristine Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000005908 glyceryl ester group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- 229940069062 dihydro-alpha-ergocryptine Drugs 0.000 description 1
- 229940069063 dihydro-beta-ergocryptine Drugs 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940040520 ergoloid mesylates Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012735 once-a-day formulation Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858502889A GB8502889D0 (en) | 1985-02-05 | 1985-02-05 | Co-dergocrine compositions |
| GB858517604A GB8517604D0 (en) | 1985-07-12 | 1985-07-12 | Dihydroergotamine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE860291L IE860291L (en) | 1986-08-05 |
| IE59293B1 true IE59293B1 (en) | 1994-02-09 |
Family
ID=26288767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE29186A IE59293B1 (en) | 1985-02-05 | 1986-02-03 | Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JPS61183225A (it) |
| KR (1) | KR920010388B1 (it) |
| AU (1) | AU597570B2 (it) |
| BE (1) | BE904152A (it) |
| CA (1) | CA1263087A (it) |
| CH (1) | CH667592A5 (it) |
| CY (1) | CY1604A (it) |
| DE (1) | DE3602577A1 (it) |
| DK (1) | DK167138B1 (it) |
| ES (1) | ES8800040A1 (it) |
| FR (1) | FR2576787B1 (it) |
| GB (1) | GB2170407B (it) |
| GR (1) | GR860310B (it) |
| HK (1) | HK57191A (it) |
| HU (1) | HU195729B (it) |
| IE (1) | IE59293B1 (it) |
| IT (1) | IT1191255B (it) |
| LU (1) | LU86289A1 (it) |
| NL (1) | NL8600161A (it) |
| NZ (1) | NZ215020A (it) |
| PH (1) | PH23384A (it) |
| PT (1) | PT81954B (it) |
| SE (1) | SE8600496L (it) |
| SG (1) | SG56191G (it) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2610827B1 (fr) * | 1987-02-18 | 1991-09-13 | Pf Medicament | Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication |
| YU47044B (sh) * | 1987-03-11 | 1994-12-28 | LEK TOVARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV n.sol.o. | Postupak za dobijanje tableta sa produženim delovanjem na bazi hidroksipropil-metilceluloze velike molekularne mase |
| EP1235574B1 (en) * | 1999-12-03 | 2005-02-02 | Polichem S.A. | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| US7771746B2 (en) | 1999-12-03 | 2010-08-10 | Polichem Sa | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| US20030153620A1 (en) | 2000-05-12 | 2003-08-14 | Meakin Timothy David | Treating eczema and/or psoriasis |
| NZ504526A (en) * | 2000-05-12 | 2003-05-30 | Meracol Corp Ltd | Treating herpes simplex symptoms using a mixture of cetyl myristate and cetyl palmitate |
| ES2299484T3 (es) | 2000-05-12 | 2008-06-01 | Meracol Corporation Limited | Tratamiento del sindrome o enfermedad de intestino irritable. |
| DE60132008T2 (de) * | 2000-05-12 | 2008-12-11 | Meracol Corp. Ltd., Takapuna | Cetylmyristat und cetylpalmitat zur behandlung von ekzemen und/oder psoriasis |
| WO2003026640A1 (en) * | 2001-09-28 | 2003-04-03 | Meracol Corporation Limited | Treating food allergies and/or food intolerances |
| CN111297815B (zh) * | 2020-04-29 | 2022-04-15 | 宝利化（南京）制药有限公司 | 一种甲磺酸二氢麦角碱缓释片及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3147187A (en) * | 1962-09-10 | 1964-09-01 | Don Hall Lab | Sustained release pharmaceutical |
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| DE3124983A1 (de) * | 1981-06-25 | 1983-01-20 | Meditest Inst Fuer Medizinisch | Arzneiformen zur oralen verabreichung |
| CH649300A5 (de) * | 1981-08-07 | 1985-05-15 | Sandoz Ag | Ergopeptinderivate, ihre herstellung und verwendung. |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3303616A1 (de) * | 1982-02-12 | 1983-08-25 | Sandoz-Patent-GmbH, 7850 Lörrach | Mutterkornalkaloide, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische zubereitungen |
| US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
| JPS604120A (ja) * | 1983-06-22 | 1985-01-10 | Shionogi & Co Ltd | 作用持続型ピナシジル製剤 |
| GB2154874B (en) * | 1984-02-29 | 1987-11-04 | Sandoz Ltd | Bromoscriptine compositions |
| GB8413795D0 (en) * | 1984-05-30 | 1984-07-04 | Sandoz Ltd | Organic compounds |
-
1986
- 1986-01-24 NL NL8600161A patent/NL8600161A/nl not_active Application Discontinuation
- 1986-01-24 HU HU86361A patent/HU195729B/hu not_active IP Right Cessation
- 1986-01-27 CH CH296/86A patent/CH667592A5/de not_active IP Right Cessation
- 1986-01-29 DE DE19863602577 patent/DE3602577A1/de not_active Ceased
- 1986-01-31 FR FR868601477A patent/FR2576787B1/fr not_active Expired - Lifetime
- 1986-02-03 BE BE1/011431A patent/BE904152A/fr not_active IP Right Cessation
- 1986-02-03 IE IE29186A patent/IE59293B1/en not_active IP Right Cessation
- 1986-02-03 KR KR1019860000698A patent/KR920010388B1/ko not_active IP Right Cessation
- 1986-02-03 CA CA000501011A patent/CA1263087A/en not_active Expired
- 1986-02-03 GB GB08602602A patent/GB2170407B/en not_active Expired
- 1986-02-03 GR GR860310A patent/GR860310B/el unknown
- 1986-02-03 DK DK052086A patent/DK167138B1/da not_active IP Right Cessation
- 1986-02-03 NZ NZ215020A patent/NZ215020A/xx unknown
- 1986-02-03 PT PT81954A patent/PT81954B/pt not_active IP Right Cessation
- 1986-02-03 AU AU52942/86A patent/AU597570B2/en not_active Ceased
- 1986-02-04 ES ES551635A patent/ES8800040A1/es not_active Expired
- 1986-02-04 LU LU86289A patent/LU86289A1/fr unknown
- 1986-02-04 JP JP61023666A patent/JPS61183225A/ja active Pending
- 1986-02-04 SE SE8600496A patent/SE8600496L/ not_active Application Discontinuation
- 1986-02-04 PH PH33379A patent/PH23384A/en unknown
- 1986-02-05 IT IT47620/86A patent/IT1191255B/it active
-
1991
- 1991-07-16 SG SG561/91A patent/SG56191G/en unknown
- 1991-07-25 HK HK571/91A patent/HK57191A/xx unknown
-
1992
- 1992-04-03 CY CY1604A patent/CY1604A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB8602602D0 (en) | 1986-03-12 |
| IE860291L (en) | 1986-08-05 |
| DK167138B1 (da) | 1993-09-06 |
| KR860006265A (ko) | 1986-09-09 |
| SE8600496L (sv) | 1986-08-06 |
| BE904152A (fr) | 1986-08-04 |
| GB2170407A (en) | 1986-08-06 |
| HU195729B (en) | 1988-07-28 |
| AU597570B2 (en) | 1990-06-07 |
| FR2576787A1 (fr) | 1986-08-08 |
| ES551635A0 (es) | 1987-10-16 |
| IT1191255B (it) | 1988-02-24 |
| IT8647620A0 (it) | 1986-02-05 |
| FR2576787B1 (fr) | 1990-01-12 |
| ES8800040A1 (es) | 1987-10-16 |
| CA1263087A (en) | 1989-11-21 |
| PT81954A (en) | 1986-03-01 |
| PT81954B (pt) | 1988-07-01 |
| DK52086A (da) | 1986-08-06 |
| CY1604A (en) | 1992-04-03 |
| KR920010388B1 (ko) | 1992-11-27 |
| NL8600161A (nl) | 1986-09-01 |
| LU86289A1 (fr) | 1986-09-02 |
| SG56191G (en) | 1991-08-23 |
| GR860310B (en) | 1986-05-27 |
| JPS61183225A (ja) | 1986-08-15 |
| CH667592A5 (de) | 1988-10-31 |
| HK57191A (en) | 1991-08-02 |
| SE8600496D0 (sv) | 1986-02-04 |
| AU5294286A (en) | 1986-08-14 |
| NZ215020A (en) | 1989-07-27 |
| DK52086D0 (da) | 1986-02-03 |
| DE3602577A1 (de) | 1986-08-28 |
| HUT41984A (en) | 1987-06-29 |
| GB2170407B (en) | 1988-10-26 |
| PH23384A (en) | 1989-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0311582B1 (en) | Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof | |
| FI89005C (fi) | Foerfarande foer framstaellning av en doseringsform av etodolac med foerdroejd utloesning | |
| SU1743332A3 (ru) | Способ получени таблеток | |
| US5980942A (en) | Zero-order sustained release matrix tablet formulations of carbamazepine | |
| CA2406373C (en) | Controlled release paracetamol composition | |
| WO2009034541A9 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| GB2196852A (en) | Sustained release composition | |
| US5399360A (en) | Pharmaceutical compositions | |
| IE59293B1 (en) | Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions | |
| GB2154874A (en) | Bromocriptine compositions | |
| WO2002049608A1 (en) | Cabergoline pharmaceutical compositions and methods of use thereof | |
| US5069911A (en) | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | |
| UA65652C2 (uk) | Таблетка з регульованим вивільненням бетагістину та спосіб її виготовлення | |
| PL191767B1 (pl) | Stabilizowane przed racemizacją stałe lub ciekłe preparaty farmaceutyczne zawierające jako składnik czynny cilansetron, sposób wytwarzania stabilizowanych przed racemizacją stałych preparatów farmaceutycznych zawierających jako składnik czynny cilansetron oraz zastosowanie dopuszczalnych fizjologicznie rozpuszczalnych w wodzie kwaśnych dodatków | |
| GB2181053A (en) | Controlled release formulation | |
| AU756338B2 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| CA1256374A (en) | Bromocriptine compositions | |
| JP2001511450A (ja) | チアガビンを含有する制御放出性の医薬組成物 | |
| DK170016B1 (da) | Præparat med kontrolleret afgivelse af det aktive stof | |
| AU598751B2 (en) | Pharmaceutical formulations with controlled release of the active substance | |
| SK11072000A3 (sk) | Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami | |
| JPH0466846B2 (it) | ||
| KR950007229B1 (ko) | 케토티펜을 함유한 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |